Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.

McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, Smith K, Strang J.

Addiction. 2018 Mar;113(3):484-493. doi: 10.1111/add.14033. Epub 2017 Nov 16.

2.

Efficacy of Conventional and Liposomal Povidone-Iodine in Infected Mesh Skin Grafts: An Exploratory Study.

Vogt PM, Hauser J, Mueller S, Bosse B, Hopp M.

Infect Dis Ther. 2017 Dec;6(4):545-555. doi: 10.1007/s40121-017-0172-z. Epub 2017 Oct 10.

3.

Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study.

Augustin M, Goepel L, Jacobi A, Bosse B, Mueller S, Hopp M.

Clin Cosmet Investig Dermatol. 2017 Sep 22;10:373-384. doi: 10.2147/CCID.S141887. eCollection 2017.

4.

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.

Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.

Eur J Pain. 2017 Oct;21(9):1528-1537. doi: 10.1002/ejp.1054. Epub 2017 Jun 22.

5.

Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.

Dupoiron D, Stachowiak A, Loewenstein O, Ellery A, Kremers W, Bosse B, Hopp M.

Eur J Pain. 2017 Oct;21(9):1485-1494. doi: 10.1002/ejp.1050. Epub 2017 May 4.

6.

Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.

Oertel WH, Hallström Y, Saletu-Zyhlarz GM, Hopp M, Bosse B, Trenkwalder C; RELOXYN Study Group.

CNS Drugs. 2016 Aug;30(8):749-60. doi: 10.1007/s40263-016-0372-1.

7.

Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials.

Blagden M, Hafer J, Duerr H, Hopp M, Bosse B.

Neurogastroenterol Motil. 2014 Dec;26(12):1792-801. doi: 10.1111/nmo.12463. Epub 2014 Oct 23.

8.

Adaptation of the steady-state PERG in early glaucoma.

Porciatti V, Bosse B, Parekh PK, Shif OA, Feuer WJ, Ventura LM.

J Glaucoma. 2014 Oct-Nov;23(8):494-500. doi: 10.1097/IJG.0b013e318285fd95.

9.

Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects.

Banitt MR, Ventura LM, Feuer WJ, Savatovsky E, Luna G, Shif O, Bosse B, Porciatti V.

Invest Ophthalmol Vis Sci. 2013 Mar 28;54(3):2346-52. doi: 10.1167/iovs.12-11026.

10.
11.

Supplemental Content

Loading ...
Support Center